Calliditas Receives the US FDA's Fast Track Designation for Setanaxib to Treat Primary Biliary Cholangitis
Shots:
- The US FDA has granted FTD to selinexor (NOX inhibitor) for the treatment of PBC. Additionally- the therapy has previously received ODD for PBC in the US & EU
- The P-II clinical trial of the therapy demonstrated anti-fibrotic activity as measured by Fibroscan and showed favorable tolerability profile along with the impact on fatigue
- The company plans to start P-II/III study for PBC in H2’21 based on results from the P-I study which evaluated higher doses of setanaxib in healthy volunteers
| Ref: Calliditas | Image: Calliditas
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com